KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanomaPier Francesco Ferrucci, Paolo A. Ascierto, Henrik Schmidt et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 178
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutationMichele Maio, Omid Hamid, Matteo S. Carlino et al.|European Journal of Cancer|2021Cited by 10